Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Dose of Irbesartan for Renoprotection in T2D with Microalbuminuria
NCT00320879Phase 4Completed
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Sep 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of irbesartan in diabetic nephropathy (DN) (3 arms), sponsored by Steno Diabetes Center Copenhagen. Primary endpoint: Urinary Albumin Excretion Rate at 10 weeks. Started Sep 2003; status: completed.
02
Drugs
irbesartan
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT00320879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00320879.